Minsheng He
C4 Therapeutics (United States)(US)
Publications by Year
Research Areas
Pharmaceutical and Antibiotic Environmental Impacts, Chemical Synthesis and Analysis, Phenothiazines and Benzothiazines Synthesis and Activities, Antibiotic Resistance in Bacteria, Asymmetric Hydrogenation and Catalysis
Most-Cited Works
- → Fluorocyclines. 2. Optimization of the C-9 Side-Chain for Antibacterial Activity and Oral Efficacy(2011)72 cited
- → Process R&D of Eravacycline: The First Fully Synthetic Fluorocycline in Clinical Development(2013)59 cited
- → 8-Azatetracyclines: Synthesis and Evaluation of a Novel Class of Tetracycline Antibacterial Agents(2011)40 cited
- → Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents(2015)17 cited
- → Synthesis and Biological Evaluation of 8-Aminomethyltetracycline Derivatives as Novel Antibacterial Agents(2013)14 cited
- → Process Development and Scale-up of Fully Synthetic Tetracycline TP-2758: A Potent Antibacterial Agent with Excellent Oral Bioavailability(2015)11 cited
- → Process Research and Development of TP-808: A Key Intermediate for the Manufacture of Synthetic Tetracyclines(2017)10 cited
- → Discovery of CFT8634, a Potent, Selective, and Orally Bioavailable Heterobifunctional Degrader of BRD9(2025)3 cited
- → CFT8634, a potent, selective and orally bioavailable BiDACTM degrader of BRD9, highlights the potential of C4T’S TORPEDO® platform to develop degraders with excellent drug-like properties against currently undruggable targets(2025)